In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will receive treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. Attainable new strategies to the prognosis and treatment of AML. (A) The identification https://brd4-targeted-therapy-abb68912.wssblogs.com/31962228/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies